ChronicleBio: Funding Rounds, Investors & CEO

About ChronicleBio

ChronicleBio helps researchers and drug developers study complex chronic illnesses. It focuses on nervous and immune system conditions, including POTS, ME/CFS, and Long COVID. The company builds research data and artificial intelligence tools to improve diagnosis and treatment development.

Rohit Gupta is co-founder and chief executive officer, while Fidji Simo is a co-founder and director. At launch, multiple clinics in the United States and India used the platform. Research collaborations also involved thousands of patients contributing data and biological samples.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
Oct 28, 2026	Nov 12, 2026	$250,000of $1.0M target	1	$250K	OptionsRule 506(b)	Form D ↗
Sep 30, 2025	Oct 15, 2025amended Nov 12, 2026	$15,366,000of $16.0M target	50	$307K	OptionsRule 506(b)	Form D/A ↗4 earlier filings
Total, two offerings		$15,616,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Why Investors Backed ChronicleBio

ChronicleBio argues that neuroimmune disorders lack data at the scale and structure needed for rigorous research. It combines biobanking and precision-medicine experience with technology and health care expertise. Its founders also have personal or family experience with the conditions. [2]

“We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale.”

Rishi Reddy · Co-founder & Executive Chairman, ChronicleBio · Company launch announcement [2]

Origin and Team

Fidji Simo, Rohit Gupta, and Rishi Reddy co-founded ChronicleBio. [2]

At launch, Simo was Instacart’s chief executive officer and was set to lead OpenAI’s applications division. Gupta had overseen centers at Stanford and UCSF. Reddy invested in health and life sciences through Tarsadia Investments. [2]

Product and Technology

ChronicleBio creates new human disease data and trains artificial intelligence models to interpret it. [1]

Its datasets combine clinical records with molecular measurements. They also connect biological samples and patient reports. Researchers use them for biomarker discovery, patient grouping, and precision therapy development. [2]

ChronicleBio works with patients, clinics, and research collaborators to collect data over time. The datasets include genetic data, immune profiling, and real-world outcomes. They support scientific exploration and clinical-trial readiness. [2]

Its approach also includes a global biobank and a decentralized clinical-trial network. [2]

Milestones

Scroll table to see all columns →

Date	What happened	Source	Coverage
Aug 5, 2025	ChronicleBio officially launched to study complex neuroimmune conditions.	[2]	—

Market

ChronicleBio estimates that complex chronic conditions affect nearly 300 million people worldwide. It argues these illnesses remain understudied and leave patients without meaningful treatments. [2]

We wrote this summary from public statements by ChronicleBio and its investors. It is not investment advice.